Fighting Cancer ... with Science
JENOMIC: BREAKING NEWS...
As Seen on CBS News:
Could Deadly Blood Disorder Be Turned Into Life-Saving Cancer Treatment?
CBS's Dr. Max Gomez reports
JENOMIC'S PLOS ONE PUBLICATION
Published JANUARY 9, 2013
AS HIGHLIGHTED ON PLOS ONE WEB SITE:
Video Demonstration: Video microscopy of breast tumor after injection of labelled sickle cells (SRBCs) shows sickle cells sticking to tumor blood vessel walls where they cluster and obstruct blood flow. In contrast, normal red blood cells (NRBCs) move freely through the tumor blood vessels without sticking or blocking blood flow.
About Jenomic Research Institute
Jenomic is a biotech company dedicated to the developing novel drugs and drug vehicles for treatment of cancer. These efforts are supported by a raft of peer- reviewed publications and worldwide patents/patent applications.
The research team is led by David S. Terman, MD, an emeritus member of the American Society of Clinical Investigation (academia's physician-scientist honor society), former Professor of Medicine and Microbiology/Immunology and Director of Cancer Biology Program at Baylor College of Medicine. Dr. Terman is cited in Who's Who in America.